Summary
Forty-five patients with non-small cell lung cancer were treated in a phase II trial with menogaril 200 mg/m2 IV every twenty-eight days by a one-hour infusion. One partial response was noted while twenty-two patients had stable disease (51 %). Progressive disease was noted in the remaining twenty-two patients. There was one fatal complication due to pancytopenia and pneumonia. Otherwise, the drug was reasonably well tolerated. At this dosage and schedule, menogaril has no substantial anti-tumor activity for patients with non-small cell lung cancer.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Krueger WC, Pschigoda M, Schpok SLF: The interaction of nogalamycin and analogs with DNA and other biopolymers. Chem-Biol Interaction 36: 1–18, 1981
Li LH, Murch LL, Wooden JM, Krueger WC, Pschigoda LM: Inhibition of DNA and RNA polymerases by nogalamycin and its analogs. (Abstr) Proc Am Assoc Cancer Res 19: 30, 1978
Neil GL, Kuentzel SL, McGovren JP: Treatment of mouse tumors with 7-con-O-Methylnogarol and other analogs of the anthracycline antibiotics, nogalamycin. Cancer Treat Rep 63: 1971–1978, 1979
Weiss GR, Bhuyan DK, Kisner DL, Von Hoff DD: 7(R)-O- Methylnogarol (MEN): antitumor activity in the human tumor cloning system. Invest New Drugs 2: 118, 1984
Joss RA et al.: Euro J Cancer Oncol 24 (2): 263–265, 1988
Author information
Authors and Affiliations
Additional information
Address for offprints: Southwest Oncology Group (SWOG-8567), Operations Office, 5430 Fredericksburg Road, Suite #618, San Antonio, TX 78229, USA
Rights and permissions
About this article
Cite this article
Vance, R.B., Crowley, J.J., Macdonald, J.S. et al. Phase II evaluation of menogaril (NSC-269148) in non-small cell lung carcinoma. Invest New Drugs 9, 73–75 (1991). https://doi.org/10.1007/BF00194549
Issue Date:
DOI: https://doi.org/10.1007/BF00194549